0RX Stock Overview
Engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Redx Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.17 |
| 52 Week High | €0.34 |
| 52 Week Low | €0.046 |
| Beta | 0.052 |
| 1 Month Change | 76.72% |
| 3 Month Change | -27.39% |
| 1 Year Change | -50.88% |
| 3 Year Change | -77.28% |
| 5 Year Change | n/a |
| Change since IPO | -71.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -2.6% |
| 1Y | -50.9% | -15.2% | 7.1% |
Return vs Industry: 0RX underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 0RX underperformed the German Market which returned 6.5% over the past year.
Price Volatility
| 0RX volatility | |
|---|---|
| 0RX Average Weekly Movement | 38.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0RX's share price has been volatile over the past 3 months.
Volatility Over Time: 0RX's weekly volatility has increased from 19% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 101 | Lisa Mary Anson | www.redxpharma.com |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn’s disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
Redx Pharma Plc Fundamentals Summary
| 0RX fundamental statistics | |
|---|---|
| Market cap | €64.96m |
| Earnings (TTM) | -€38.64m |
| Revenue (TTM) | €4.90m |
13.3x
P/S Ratio-1.7x
P/E RatioIs 0RX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RX income statement (TTM) | |
|---|---|
| Revenue | UK£4.20m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£4.20m |
| Other Expenses | UK£37.36m |
| Earnings | -UK£33.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 100.00% |
| Net Profit Margin | -789.05% |
| Debt/Equity Ratio | 468.9% |
How did 0RX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/15 17:18 |
| End of Day Share Price | 2024/05/13 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Redx Pharma Plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Martin Hall | Hardman & Co. |
| Michael Mitchell | Panmure Liberum Historic (Panmure Gordon) |